Literature DB >> 17145775

Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk.

Antonius E van Herwaarden1, Els Wagenaar, Gracia Merino, Johan W Jonker, Hilde Rosing, Jos H Beijnen, Alfred H Schinkel.   

Abstract

The multidrug transporter breast cancer resistance protein (BCRP/ABCG2) is strongly induced in the mammary gland during pregnancy and lactation. We here demonstrate that BCRP is responsible for pumping riboflavin (vitamin B(2)) into milk, thus supplying the young with this important nutrient. In Bcrp1(-/-) mice, milk secretion of riboflavin was reduced >60-fold compared to that in wild-type mice. Yet, under laboratory conditions, Bcrp1(-/-) pups showed no riboflavin deficiency due to concomitant milk secretion of its cofactor flavin adenine dinucleotide, which was not affected. Thus, two independent secretion mechanisms supply vitamin B(2) equivalents to milk. BCRP is the first active riboflavin efflux transporter identified in mammals and the first transporter shown to concentrate a vitamin into milk. BCRP activity elsewhere in the body protects against xenotoxins by reducing their absorption and mediating their excretion. Indeed, Bcrp1 activity increased excretion of riboflavin into the intestine and decreased its systemic availability in adult mice. Surprisingly, the paradoxical dual utilization of BCRP as a xenotoxin and a riboflavin pump is evolutionarily conserved among mammals as diverse as mice and humans. This study establishes the principle that an ABC transporter can transport a vitamin into milk and raises the possibility that other vitamins and nutrients are likewise secreted into milk by ABC transporters.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17145775      PMCID: PMC1800714          DOI: 10.1128/MCB.01621-06

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  22 in total

Review 1.  Current perspectives on the cellular uptake and trafficking of riboflavin.

Authors:  Amy B Foraker; Chandra M Khantwal; Peter W Swaan
Journal:  Adv Drug Deliv Rev       Date:  2003-11-14       Impact factor: 15.470

2.  Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.

Authors:  John D Allen; Arnold van Loevezijn; Jeany M Lakhai; Martin van der Valk; Olaf van Tellingen; Glen Reid; Jan H M Schellens; Gerrit-Jan Koomen; Alfred H Schinkel
Journal:  Mol Cancer Ther       Date:  2002-04       Impact factor: 6.261

3.  C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.

Authors:  Yasuo Imai; Minoru Nakane; Kumie Kage; Satomi Tsukahara; Etsuko Ishikawa; Takashi Tsuruo; Yoshio Miki; Yoshikazu Sugimoto
Journal:  Mol Cancer Ther       Date:  2002-06       Impact factor: 6.261

4.  Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.

Authors:  H A Bardelmeijer; J H Beijnen; K R Brouwer; H Rosing; W J Nooijen; J H Schellens; O van Tellingen
Journal:  Clin Cancer Res       Date:  2000-11       Impact factor: 12.531

5.  Involvement of a receptor-mediated component in cellular translocation of riboflavin.

Authors:  S N Huang; P W Swaan
Journal:  J Pharmacol Exp Ther       Date:  2000-07       Impact factor: 4.030

Review 6.  The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins.

Authors:  Antonius E van Herwaarden; Alfred H Schinkel
Journal:  Trends Pharmacol Sci       Date:  2005-12-06       Impact factor: 14.819

7.  The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria.

Authors:  Johan W Jonker; Marije Buitelaar; Els Wagenaar; Martin A Van Der Valk; George L Scheffer; Rik J Scheper; Torsten Plosch; Folkert Kuipers; Ronald P J Oude Elferink; Hilde Rosing; Jos H Beijnen; Alfred H Schinkel
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-12       Impact factor: 11.205

8.  The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.

Authors:  Antonius E van Herwaarden; Johan W Jonker; Els Wagenaar; Remco F Brinkhuis; Jan H M Schellens; Jos H Beijnen; Alfred H Schinkel
Journal:  Cancer Res       Date:  2003-10-01       Impact factor: 12.701

9.  Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine.

Authors:  Charis P Zamber; Jatinder K Lamba; Kazuto Yasuda; Jennifer Farnum; Kenneth Thummel; John D Schuetz; Erin G Schuetz
Journal:  Pharmacogenetics       Date:  2003-01

Review 10.  Riboflavin (vitamin B-2) and health.

Authors:  Hilary J Powers
Journal:  Am J Clin Nutr       Date:  2003-06       Impact factor: 7.045

View more
  57 in total

1.  ABCG2 null alleles define the Jr(a-) blood group phenotype.

Authors:  Teresa Zelinski; Gail Coghlan; Xiao-Qing Liu; Marion E Reid
Journal:  Nat Genet       Date:  2012-01-15       Impact factor: 38.330

2.  Effect of ABCG2, PPARGC1A, OLR1 and SCD1 gene polymorphism on estimated breeding values for functional and production traits in Polish Holstein-Friesian bulls.

Authors:  J Komisarek; Z Dorynek
Journal:  J Appl Genet       Date:  2009       Impact factor: 3.240

Review 3.  Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies.

Authors:  Chung-Pu Wu; Anna Maria Calcagno; Suresh V Ambudkar
Journal:  Curr Mol Pharmacol       Date:  2008-06       Impact factor: 3.339

4.  Efflux transporters: newly appreciated roles in protection against pollutants.

Authors:  David Epel; Till Luckenbach; Charlotte N Stevenson; Laura A Macmanus-Spencer; Amro Hamdoun; Tvrtko Smital
Journal:  Environ Sci Technol       Date:  2008-06-01       Impact factor: 9.028

5.  Identification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay.

Authors:  Yimao Zhang; Youngjoo Byun; Yunzhao R Ren; Jun O Liu; John Laterra; Martin G Pomper
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

Review 6.  ABCG transporters and disease.

Authors:  Owen M Woodward; Anna Köttgen; Michael Köttgen
Journal:  FEBS J       Date:  2011-06-13       Impact factor: 5.542

7.  Intracellular autofluorescence: a biomarker for epithelial cancer stem cells.

Authors:  Irene Miranda-Lorenzo; Jorge Dorado; Enza Lonardo; Sonia Alcala; Alicia G Serrano; Jenifer Clausell-Tormos; Michele Cioffi; Diego Megias; Sladjana Zagorac; Anamaria Balic; Manuel Hidalgo; Mert Erkan; Joerg Kleeff; Aldo Scarpa; Bruno Sainz; Christopher Heeschen
Journal:  Nat Methods       Date:  2014-09-28       Impact factor: 28.547

Review 8.  Nutrient transport in the mammary gland: calcium, trace minerals and water soluble vitamins.

Authors:  Nicolas Montalbetti; Marianela G Dalghi; Christiane Albrecht; Matthias A Hediger
Journal:  J Mammary Gland Biol Neoplasia       Date:  2014-02-25       Impact factor: 2.673

Review 9.  Intestinal and hepatic drug transporters: pharmacokinetic, pathophysiological, and pharmacogenetic roles.

Authors:  Tomohiro Terada; Daiki Hira
Journal:  J Gastroenterol       Date:  2015-03-14       Impact factor: 7.527

10.  BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure.

Authors:  J M Day; P A Foster; H J Tutill; S P Newman; Y T Ho; M P Leese; B V L Potter; M J Reed; A Purohit
Journal:  Br J Cancer       Date:  2009-01-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.